Brazilian biotechnology startup BioLinker has successfully raised $1.7 million in a new funding round as it looks to scale its operations, expand its domestic DNA production, and integrate artificial intelligence into its research and development framework. The investment is led by venture capital firm Axcell, which contributed $1.4 million, alongside approximately $240,000 provided by the São Paulo Research Foundation through its PIPE Phase 2 program. The fresh capital infusion marks a significant milestone for the firm as it positions itself at the intersection of synthetic biology, automation, and regional technological development in Brazil.
Founded in 2018 by a group of scientists and researchers hailing from the University of São Paulo, BioLinker specializes in the development and manufacture of high-purity recombinant proteins utilizing advanced synthetic biology and genetic engineering techniques. The company’s innovative products serve critical functions across multiple sectors, providing essential material and support for scientific research, advanced diagnostics, and various industrial applications. Over the years, the startup has carved out a distinct niche within the Latin American biotech landscape by offering reliable, locally produced biological components that reduce the region’s historical reliance on imported research materials.
With the newly secured capital, BioLinker has outlined ambitious growth plans centered around regional expansion and technological modernization. A cornerstone of this strategy involves the construction of a state-of-the-art, automated laboratory situated at the Amazon BioBusiness Center in Manaus. This upcoming facility is designed to leverage cutting-edge robotics to generate biological data at scale. By automating data collection and synthesis, the company aims to acquire the high-volume datasets necessary to train and refine sophisticated artificial intelligence models tailored for biological and genetic research.
In addition to building out its automated laboratory infrastructure in Manaus, BioLinker intends to significantly broaden its DNA production capabilities within Brazil. The expansion is expected to bolster the domestic bioeconomy by establishing localized supply chains for critical biotechnology components. To support these growing operational demands, the startup also plans to double its workforce, expanding its current team from 12 to 24 employees by bringing in specialized talent across engineering, biology, data science, and laboratory operations.
Despite closing this latest injection of capital, BioLinker’s current funding round remains actively open. Company leadership is currently seeking a strategic international investor to support its broader global expansion initiatives and provide external expertise ahead of a planned Series A funding round scheduled to take place within the next two years. Unlike many early-stage startups that rely entirely on speculative growth, BioLinker already generates stable, recurring revenue from its commercial operations. Company executives expect that the newly acquired capital, combined with existing revenue streams, will be sufficient to fully fund three years of independent operations and strategic development.
